Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated T1D. However, subtleties in dosage, choice of branded insulin, choice of regimen, and order in which regimens are attempted do exist between patient subpopulations and between physician types. In addition, the launch of biosimilar insulins is having a profound effect on the T1D therapy market, and we are witnessing an intricate interplay of physician and payer attitudes toward this new treatment option.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.
PRIMARY RESEARCH INFO
Type 1 Diabetes Current Treatment: Physician Insights is a primary market research study, evaluating physician self-reported prescribing and treatment practices for type 1 diabetes. E-mail invitations were sent to endocrinologists and PCPs to participate in an online survey. 51 endocrinologists and 51 PCPs completed the survey. The survey took approximately 30 minutes to complete. Fieldwork occurred in January 2018. To qualify, respondents met the following screening criteria:
After meeting the screening criteria, respondents were directed to an online survey, and respondents were paid an honorarium for their participation. Statistical significance testing was done when appropriate, including anticipated vs. current allocations, subgroups, and brands.
Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly
Lantus, Levemir, Toujeo, Tresiba, Basaglar, Novolog, Humalog, Apidra